索利那新联合PKRP治疗前列腺增生合并膀胱过度活动症的疗效观察

Observation on Efficacy of Solifenacin Combined with PKRP in the Treatment of Benign Prostatic Hyperplasia Complicated with Overactive Bladder

目的:观察索利那新联合经尿道前列腺等离子双极电切术(PKRP)治疗前列腺良性增生(BPH)合并膀胱过度活动症(OAB)的治疗效果。方法 :选取2016年1月-2017年6月我院收治的96例BPH合并OAB患者作为研究对象,按随机数字表法分为对照组与研究组,各48例。对照组采取PKRP治疗,研究组于PKRP治疗基础上联合应用索利那新(5 mg,qd)治疗;治疗后评估两组临床疗效,观察治疗前后两组储尿期症状评分(USPSS)、排尿期症状评分(VSS)、国际前列腺症状评分(IPSS)、国际前列腺生活质量评分(QOL)、OAB自我评价量表(OABSS)、膀胱动力学指标、尿流动力学指标的变化情况以及不良反应发生情况。结果:研究组总有效率为97.92%,对照组总有效率为85.42%,研究组临床疗效优于对照组(P<0.05)。治疗后两组USPSS、VSS、OABSS、IPSS、QOL评分均较治疗前改善,且研究组均优于对照组(P<0.05)。治疗后两组残余尿量(PVR)、最大尿流率(Qmax)、平均尿流率(Qave)、排尿量(VV)均较治疗前改善,且研究组均优于对照组(P<0.05)。治疗后两组最大膀胱测压容量(MCC)、膀胱顺应性(BC)均较治疗前改善,且研究组均优于对照组(P<0.05)。研究组不良反应发生率为10.42%,对照组不良反应发生率为27.08%,研究组低于对照组(P<0.05)。结论 :索利那新能够提高PKRP治疗前列腺增生合并膀胱过度活动症的临床疗效,进一步改善临床症状,提高患者生活质量,降低术后不良反应发生率。

Objective:To observe the efficacy of solifenacin combined with transurethral bipolar plasmakinetic resection of prostate(PKRP) in the treatment of benign prostatic hyperplasia(BPH) complicated with overactive bladder(OAB). Methods:96 patients with BPH complicated with OAB treated in our hospital from January 2016 to June 2017 were selected as subjects and divided into control group and study group according to the random number table method, 48 cases in each group. The patients in the control group were treated by PKRP. The patients in the study group were treated with solifenacin(5 mg, qd) on the basis of PKRP treatment. After treatment, the clinical efficacy of the two groups was evaluated, and the urine storage symptom score(USPSS), micturition symptom score(VSS), International Prostate Symptom Score(IPSS), International Prostate Quality of Life(QOL), OAB self-assessment scale(OABSS), bladder dynamics index, urodynamic index and adverse reactionss before and after treatment were observed. Results:The total effective rate was 97.92% in the study group and 85.42% in the control group. The clinical efficacy of the study group was better than that of the control group(P<0.05). The USPSS, VSS, OABSS, IPSS and QOL scores in the two groups after treatment were improved compared with those before treatment, and the study group was superior to the control group(P<0.05). The postvoid residual urine volume(PVR), maximum urinary flow rate(Qmax), average urinary flow rate(Qave) and urine volume(VV) in the two groups after treatment were improved compared with those before treatment, and the study group was superior to the control group(P<0.05). The maximum cystometric capacity(MCC) and bladder compliance(BC) in the two groups after treatment were improved compared with those before treatment, and the study group was superior to the control group(P<0.05). The incidence of adverse reactions was 10.42% in the study group and 27.08% in the control group. The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05). Conclusion:Solifenacin can improve the clinical efficacy of PKRP in the treatment of benign prostatic hyperplasia complicated with overactive bladder, further improve clinical symptoms, improve the quality of life of patients and reduce the incidence of adverse reactions after surgery.